Receive The Newest Study Notifications

ASCO 2019: Use of Broader Criteria for Clinical Trial Enrollment Would Double Number of Eligible Patients With Lung Cancer

by Lance Smith | Jun 4, 2019 | Study Scavenger Clinical Trial Recruitment Platform

DEEPER INSIGHTS Correlation of Angiogenesis Biomarkers with Early Metastatic Progression in NSCLC A study looking at 10,500 health records of advanced non-small cell lung cancer (aNSCLC) patients from ASCO’s CancerLinQ database found that the use of expanded clinical...

Verona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPD

by Lance Smith | Jun 4, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Ensifentrine delivery via MDI inhalers could dramatically expand clinical utility and commercial opportunity Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces the initiation...

Scholar Rock Announces Positive Final Results from Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers

by Lance Smith | Jun 4, 2019 | Study Scavenger Clinical Trial Recruitment Platform

–  SRK-015 was well-tolerated in healthy volunteers across all tested doses, supporting evaluation in the ongoing Phase 2 TOPAZ trial in Spinal Muscular Atrophy (SMA) –  Pharmacodynamic results from the completed multiple-ascending dose portion of the...

Arcutis Announces Initiation of Phase 2a Clinical Trial of ARQ-151 as a Potential Topical Treatment for Atopic Dermatitis

by Lance Smith | Jun 4, 2019 | Study Scavenger Clinical Trial Recruitment Platform

ARQ-151 Potential “Best in Class” Topical PDE4 inhibitor ARQ-151 is 50- to 300-fold more potent than approved PDE4 inhibitors Phase 2a Topline Data Anticipated Year End 2019 Westlake Village, CA, June 3, 2019 – Arcutis, Inc., a privately held...

NantKwest Launches First-in-Human Targeted NK Phase I Clinical Trial of CD19 T-haNK Cell Therapy in Lymphoma Patients

by Lance Smith | Jun 4, 2019 | Study Scavenger Clinical Trial Recruitment Platform

NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and other diseases, today announced that...

Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Pemigatinib as a First-Line Therapy for Cholangiocarcinoma

by Lance Smith | Jun 4, 2019 | Study Scavenger Clinical Trial Recruitment Platform

– Incyte (Nasdaq:INCY) today announced that the first patient has been treated in FIGHT-302, an open-label Phase 3 study evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, compared to gemcitabine with cisplatin...